Achieving appropriate, safe, and patient-centered lung cancer screening
Achieving appropriate, safe, and patient-centered lung cancer screening
批准号:
10296365
负责人:
Renda Soylemez Wiener
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-01-01 至 2021-12-31
关键词:
AddressAdvisory CommitteesAffectBeliefCancer EtiologyCaringCause of DeathCessation of lifeCharacteristicsClinicalComplementDataDecision MakingDemographic FactorsDevelopmentDisadvantagedDistressEnsureEquilibriumFutureGoalsGuidelinesHealthHealth PrioritiesHealth PromotionHealth StatusHealthcareHomelessnessInterventionInterviewKnowledgeLeadLearningLifeLife ExpectancyLogistic RegressionsLungLung CAT ScanLung noduleMalignant neoplasm of lungMethodsMinorityModelingOperative Surgical ProceduresOutcomeParticipantPatient SelectionPatientsPersonsPositioning AttributePredictive FactorPreventive servicePrimary Health CareProceduresProcessPulmonologyQualitative ResearchRecommendationResearchResourcesRiskRuralSavingsScientific Advances and AccomplishmentsScreening ResultSiteSmokerSurvival AnalysisTestingTranslatingUncertaintyVariantVeteransVulnerable PopulationsWorkagedbasecohortcomputed tomography screeningdesigndisorder preventioneffectiveness implementation studyexperienceimprovedlung cancer screeningpatient orientedpersonalized decisionpoint of carepredictive modelingpreferenceprogramssafe patientscreeningshared decision makingsupport toolstoolwastingwillingness
中文摘要
背景:肺癌筛查(LCS)可降低肺癌死亡率,但也可能造成危害
英文摘要
Background: Lung cancer screening (LCS) reduces lung cancer death, but can also cause harm, especially
when applied to patients with co-existing serious health problems. Recognizing these trade-offs, guidelines
recommend that persons with “a health problem that substantially limits life expectancy or ability to have
curative lung surgery” should not be screened, and that all patients considering LCS should undergo a shared
decision-making (SDM) process to review LCS benefits and harms with their clinicians. Yet these
recommendations are difficult to achieve, as there is little evidence to guide clinicians on which health
problems or other patient factors tip the balance of LCS from net benefit to net harm, and little is known about
Veteran and clinician approaches to and needs for LCS decision-making when anticipated benefit is marginal.
Objectives: We propose a sequential explanatory mixed methods study with the following 3 specific aims:
1. Identify factors that predict little LCS benefit due to limited life expectancy or increased LCS harms;
2. Identify clinical patient factors associated with real-world clinician and Veteran LCS decisions; and
3. Characterize approaches to and needs for decision-making when predicted LCS benefit is marginal.
Methods: Aim 1a. To determine when competing (non-lung cancer) causes of death limit LCS benefit, we will
conduct a survival analysis among LCS-eligible but unscreened Veterans, building a competing risks model
and applying recursive partitioning to identify clinically meaningful risk groups. Aim 1b. We will build a model to
identify combinations of patient factors that predict complications of invasive procedures for LCS-detected
findings. Aim 2: We will compare how well factors associated with actual LCS decisions align with factors that
predict little LCS benefit (Aim 1 models), using data from 10 VA sites that tracked rates at which LCS-eligible
Veterans were deemed “too sick” for LCS, were offered LCS, and accepted LCS. We will build mixed effects
logistic regression models to complete these subaims: 2a-Identify patient factors associated with clinicians
deeming Veterans “not appropriate” for LCS, characterizing variation across sites in offering LCS, and whether
vulnerable groups (minorities, rural, homeless) are disproportionately deemed “not appropriate” for LCS. 2b-
Identify clinical and demographic factors associated with Veteran decisions to decline vs accept LCS. Aim 3:
We will interview up to 30 clinicians and 30 Veterans (15 who accepted, 15 who declined LCS) for whom
predicted LCS benefit is marginal based on our Aim 1 models. For clinicians, we will explore beliefs about,
expected outcomes of, and site-level influences on LCS decision-making, presenting vignettes to learn how
providing predicted LCS benefit (Aim 1 models) affects LCS decision-making. For patients, we will explore
experiences with LCS discussions, health priorities relative to LCS, and other influences on decision-making.
For all participants, we will assess informational needs and preferences to support SDM at the point of care.
Anticipated Impacts on Veteran's Healthcare: To maximize the life-saving potential of LCS without creating
additional harms and wasting VA resources, LCS must be applied appropriately. This proposal will lay the
groundwork to inform future development, testing, and implementation of a personalized decision tool to
optimize patient selection for LCS and facilitate SDM between Veterans and VA clinicians at the point of care.
This work is essential to achieve safe, appropriate, and Veteran-centered care as lung cancer screening is
implemented across VA – a priority for our partners in the National Center for Health Promotion & Disease
Prevention, the Office of Primary Care, and the National Program Office for Pulmonary Medicine. This work
addresses Secretary Shulkin’s priority to focus resources efficiently on high-impact problems for Veterans.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Factors and Outcomes Associated with Inappropriate Prescribing of Phosphodiesterase-5-Inhibitors for Pulmonary Hypertension
-
批准号:10308568
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Renda Soylemez Wiener
-
依托单位:
Factors and Outcomes Associated with Inappropriate Prescribing of Phosphodiesterase-5-Inhibitors for Pulmonary Hypertension
-
批准号:10308380
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Renda Soylemez Wiener
-
依托单位:
Factors and Outcomes Associated with Inappropriate Prescribing of Phosphodiesterase-5-Inhibitors for Pulmonary Hypertension
-
批准号:10016133
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Renda Soylemez Wiener
-
依托单位:
Factors and Outcomes Associated with Inappropriate Prescribing of Phosphodiesterase-5-Inhibitors for Pulmonary Hypertension
-
批准号:9927919
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Renda Soylemez Wiener
-
依托单位:
Factors and Outcomes Associated with Inappropriate Prescribing of Phosphodiesterase-5-Inhibitors for Pulmonary Hypertension
-
批准号:9079779
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Renda Soylemez Wiener
-
依托单位:
Factors and Outcomes Associated with Inappropriate Prescribing of Phosphodiesterase-5-Inhibitors for Pulmonary Hypertension
-
批准号:10296123
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2016
-
负责人:Renda Soylemez Wiener
-
依托单位:
Progressing towards implementation of lung cancer screening in the VHA
-
批准号:8540738
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2013
-
负责人:Renda Soylemez Wiener
-
依托单位:
Improving decisions about evaluating pulmonary nodules for lung cancer
-
批准号:8130773
-
项目类别:
-
资助金额:$16.92万
-
财政年份:2009
-
负责人:Renda Soylemez Wiener
-
依托单位:
Improving decisions about evaluating pulmonary nodules for lung cancer
-
批准号:8319530
-
项目类别:
-
资助金额:$16.92万
-
财政年份:2009
-
负责人:Renda Soylemez Wiener
-
依托单位:
Improving decisions about evaluating pulmonary nodules for lung cancer
-
批准号:8005968
-
项目类别:
-
资助金额:$16.9万
-
财政年份:2009
-
负责人:Renda Soylemez Wiener
-
依托单位:
Improving decisions about evaluating pulmonary nodules for lung cancer
-
批准号:7787236
-
项目类别:
-
资助金额:$1.39万
-
财政年份:2009
-
负责人:Renda Soylemez Wiener
-
依托单位:
Improving decisions about evaluating pulmonary nodules for lung cancer
-
批准号:8532653
-
项目类别:
-
资助金额:$16.92万
-
财政年份:2009
-
负责人:Renda Soylemez Wiener
-
依托单位:
Improving decisions about evaluating pulmonary nodules for lung cancer
-
批准号:7937064
-
项目类别:
-
资助金额:$16.92万
-
财政年份:2009
-
负责人:Renda Soylemez Wiener
-
依托单位:
海外基金